{
    "nct_id": "NCT04665843",
    "official_title": "A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck",
    "inclusion_criteria": "* Histologically or cytologically confirmed recurrent/metastatic SCCHN involving the oropharynx, oral cavity, larynx, or hypopharynx, that is considered incurable by local therapies\n* Known results from human papillomavirus (HPV) status test for oropharyngeal carcinoma\n* No prior systemic therapy for metastatic and/or recurrent SCCHN\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Tumor PD-L1 expression as determined by PD-L1 immunohistochemistry assay\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Life expectancy >=12 weeks\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Disease suitable for local therapy with curative intent\n* Progressive or recurrent disease within 6 months of the last dose of curative intent systemic treatment for locally advanced SCCHN\n* Rapidly progressing disease in the opinion of the treating investigator\n* Grade >=2 unresolved toxicity related to surgery or other prior therapies\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* History of leptomeningeal disease\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* History of additional malignancy other than SCCHN within 5 years prior to randomization\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-TIGIT, anti-PD-L1, and anti-PD-1 therapeutic antibodies\n* Treatment with systemic immunostimulatory agents or systemic immunosuppressive medication\n* Pregnancy or breastfeeding",
    "miscellaneous_criteria": "Key"
}